• On 7 April 2026, Alloy Therapeutics announced a collaboration and license agreement granting Biogen access to its proprietary AntiClastic antisense oligonucleotide (ASO) platform to develop antisense therapeutics against multiple undisclosed RNA targets, with Alloy receiving an upfront payment plus potential milestones and tiered royalties.
• A key angle for investors is that this deal pairs Biogen’s neurological drug development expertise with a next-generation ASO platform specifically engineered to address potency and therapeutic index challenges that have constrained antisense drugs.
• We’ll now examine how Biogen’s access to Alloy’s AntiClastic ASO Platform could influence its investment narrative and long-term pipeline outlook.

We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Biogen Investment Narrative Recap

To own Biogen, you generally need to believe its neurology focus and newer launches can offset pressure on the older MS franchise and margin headwinds from pricing and biosimilars. The Alloy Therapeutics ASO deal looks incremental near term, with limited impact on the key short term catalyst around Alzheimer’s and rare disease execution, or on the central risk that a handful of launches carry most of the business risk.

The Alloy collaboration fits a recent pattern of Biogen leaning into external platforms, alongside the March 25, 2026 Alteogen ALT B4 subcutaneous license for up to two biologics. Together, these moves underline how Biogen is trying to deepen its neurology and genetic medicines toolkit around core catalysts like LEQEMBI and salanersen, while still facing real questions about whether increased R&D spend and partnership commitments will translate into durable, broad based earnings strength.

Yet against this backdrop, investors should be aware that rising R&D commitments and trial costs could...

Biogen's narrative projects $9.4 billion revenue and $2.1 billion earnings by 2028.

Uncover how Biogen's forecasts yield a $205.67 fair value, a 14% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts already saw Biogen reaching about US$10.1 billion of revenue and US$3.3 billion of earnings by 2028, and the Alloy ASO news could either reinforce or challenge those views, depending on how you weigh the potential upside of more productive partnerships against the risk of heavier R&D spending eating into margins.

Explore 7 other fair value estimates on Biogen - why the stock might be worth 17% less than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Biogen research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Biogen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Biogen's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.
• Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.
• Uncover the next big thing with 29 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.